Rapamycin (sirolimus)
Rapamycin, also called sirolimus, is a prescription drug approved to prevent kidney transplant rejection. It is not a peptide. It extends lifespan in mice more reliably than any other drug, and many people take it off-label hoping for the same. The first year-long human trial did not meet its main goal.
- Legal lane: FDA-approved for transplant and a rare lung disease. Longevity use is off-label.
- Evidence grade: B for longevity: one real trial, small and with a missed main goal. A for the approved uses.
- Form: tablet or liquid by mouth
- Brand: Rapamune, and generics
What it is
Rapamycin blocks mTOR, a switch inside cells that drives growth. At transplant doses, taken daily, it suppresses the immune system. The longevity idea is that a lower dose taken once a week might slow aging without that effect. Whether it does is the open question.
What the evidence shows
- Animals: it extends lifespan in mice, in results repeated across laboratories.
- People: the PEARL trial, published in April 2025, enrolled 125 adults aged 50 to 85 and gave placebo, 5 mg or 10 mg once a week for 48 weeks. It did not reduce belly fat, which was its main goal. The drug appeared safe over the year. Women on the higher dose gained lean mass and reported less pain.
PEARL did not test whether rapamycin slows aging or extends life. No human trial has.
Legal status
- FDA-approved since 1999 to prevent rejection after kidney transplant, and for lymphangioleiomyomatosis, a rare lung disease.
- Prescribing it for longevity is off-label. Insurance does not cover that use.
- Prescription only. It is not a controlled substance.
Label and trial dosing
For the rare lung disease, the label starts at 2 mg a day and adjusts the dose to a target blood level. Transplant dosing is also guided by blood levels.
The longevity trial used something different: 5 mg or 10 mg once a week. That is what was tested, in a monitored study. It is not a label dose and not a recommendation.
Safety
- Boxed warning: immune suppression, with a higher risk of infection and possibly of cancer, at the doses used in transplant.
- Cholesterol: raised cholesterol is among the label's listed effects.
- Mouth sores: a well-known side effect of this drug class.
- Who should be most careful: anyone with an active infection, a cancer history or a weakened immune system. This is a decision for a clinician who knows your history.
- The weekly doses used for longevity have one year of trial data in about a hundred people. Longer-term safety at those doses is unknown.
Common questions
Is rapamycin a peptide?
No. It is a small-molecule prescription drug taken by mouth.
Does rapamycin slow aging in humans?
Nobody knows. It extends lifespan in mice. The one year-long human trial did not test aging itself and missed its main goal, which was reducing belly fat.
Is rapamycin FDA-approved for longevity?
No. It is approved for kidney transplant and a rare lung disease. Longevity use is off-label.
What dose did the longevity trial use?
5 mg or 10 mg once a week for 48 weeks, in a monitored study.
Ask an AI about this page
Opens the assistant with a question about this page already typed in. You can edit it before sending.
Ask ChatGPTAsk ClaudeAsk Perplexity
These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.
Sources
- Pfizer: Rapamune prescribing information, including the boxed warning and dosing
- PEARL trial: safety and efficacy of rapamycin on healthspan metrics after one year (preprint of the published paper)
- Summary of the PEARL results as published in Aging, April 2025
- Food Medicine Center: review of the rapamycin longevity evidence